Immatics Announces Full Year 2023 Financial Results and Corporate Update
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
ARTES Biotechnology GmbH announced today that Volker Jenzelewski reinforces the executive board of ARTES as Managing Dir…
Messenger RNA (mRNA) nanomedicines, a ground-breaking technology that has led to the development of the first approved C…
Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advan…
New partnership will harness Moderna’s mRNA rapid-response platform, clinically validated during the COVID-19 pandemic,…
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous…
Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreem…
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinic Patient…
Preclinical data published in Frontiers in Immunology, a leading peer-reviewed journal Induction of pro-inflammatory…